Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

18.470
+0.6003.36%
Volume:5.10M
Turnover:93.69M
Market Cap:48.91B
PE:12.45
High:18.610
Open:17.880
Low:17.640
Close:17.870
52wk High:26.110
52wk Low:14.505
Shares:2.65B
HK Float Shares:530.00M
Volume Ratio:2.72
T/O Rate:0.96%
Dividend:0.46
Dividend Rate:2.47%
EPS(LYR):1.484
ROE:6.95%
ROA:1.40%
PB:0.86
PE(LYR):12.45
PS:0.98

Loading ...

FOSUN PHARMA Keeps Share Capital Unchanged in July 2026 Monthly Return

Bulletin Express
·
Aug 06

Fosun Pharma Units Get Registration Nod for Two Drugs in China

MT Newswires Live
·
Aug 03

Fosun Pharma Wins NMPA Nod for Empagliflozin–Metformin SR Tablets, Targeting China’s USD 674 Million Diabetes Market

Bulletin Express
·
Aug 03

Fosun Pharma Subsidiary Secures NMPA Green Light for Pediatric Constipation Treatment

Bulletin Express
·
Aug 03

Shanghai Fosun Pharma - Drug Registration Application for Empagliflozin & Metformin Hydrochloride Sustained-Release Tablets(Iii)Approved by Nmpa

THOMSON REUTERS
·
Aug 03

Shanghai Fosun Pharma - Registration Application for Polyethylene Glycol (3350) and Electrolytes Powder Approved by Nmpa

THOMSON REUTERS
·
Aug 03

Shanghai Fosun Pharmaceutical Secures Regulatory Approval for Diabetes Combination Drug

Stock News
·
Aug 03

Sinopharm Group Stock Falls 1.5% in Hong Kong

Dow Jones
·
Jul 31

Fosun Pharma's investment fund successfully completes registration with securities authorities

Stock News
·
Jul 29

Sinopharm Group Stock Climbs 2.6% in Hong Kong

Dow Jones
·
Jul 29

Sinopharm Group Stock Climbs 2.0% in Hong Kong

Dow Jones
·
Jul 27

Fosun Pharma Gains Approval for Clinical Trial of Parkinson's Disease Treatment DM1001

Deep News
·
Jul 26

Fosun Pharma Unit Gets China Clinical Trial Approval for Parkinson's Drug

MT Newswires Live
·
Jul 24

Shanghai Fosun Pharma - Approval from National Medical Products Administration for Clinical Trial of Dm1001 Formulation

THOMSON REUTERS
·
Jul 24

Fosun Pharma Subsidiary Gains Green Light for DM1001 Drug Trial in Parkinson's Treatment

Stock News
·
Jul 24

Sinopharm Group Stock Falls 1.9% in Hong Kong

Dow Jones
·
Jul 22

Sinopharm Group Stock Slides 1.7% in Hong Kong

Dow Jones
·
Jul 21

Fosun Pharma Achieves Fourth Consecutive Year on China's Best Managed Companies List

Deep News
·
Jul 20

Sinopharm Group Stock Climbs 2.1% in Hong Kong

Dow Jones
·
Jul 16

Fosun Pharma Receives NMPA Clearance to Begin Phase I Trial of siRNA Candidate FXR0906 for Hypertriglyceridemia

Bulletin Express
·
Jul 15